Department of Dermatology and Venereology, Medical University of Bialystok, Zurawia 14 St, 15-540, Białystok, Poland.
Department of Infectious Diseases and Hepatology, Medical University of Bialystok, Zurawia 14 St, 15-540, Białystok, Poland.
Arch Dermatol Res. 2019 Jul;311(5):389-397. doi: 10.1007/s00403-019-01917-w. Epub 2019 Apr 16.
Fatty acid-binding proteins play an inconclusive role in lipid metabolism and cardiometabolic diseases (CMDs) which are closely related with psoriasis. Aim of the study was to investigate the diagnostic value of serum liver fatty acid-binding protein (FABP1) level and associations with disease severity, inflammation or metabolic parameters and influence of systemic treatment in psoriatic patients. The study included thirty-three patients with active plaque-type psoriasis and eleven healthy volunteers. Blood samples were obtained before and after 12 weeks of therapy with methotrexate and acitretin. Serum FABP1 concentrations were analyzed by the enzyme-linked immunosorbent assay. Statistical analysis was performed for correlation of FABP1 with anthropometric, metabolic or inflammatory indices and treatment used. Serum liver-type FABP levels were significantly increased in psoriatic patients compared to the controls (p < 0.001). No statistical correlations between FABP1 and PASI (p = 0.25) was noted, however patients with severe psoriasis had the highest level of FABP1. No significance with metabolic parameters was obtained, beside a positive significant relation with BMI after therapy (p = 0.03). Liver-type FABP significantly correlated with CRP (p = 0.01) and morphotic blood elements. Systemic treatment combined resulted in significant decrease of FABP1 (p = 0.04), regardless of the drug: p = 0.1 in acitretin group, p = 0.3 in methotrexate group. Liver-type FABP might be a novel marker of psoriasis and predictor of clinical response to systemic therapy. FABP1 could be involved in CMDs risk assessment and perhaps link psoriasis with hematological disorders.
脂肪酸结合蛋白在脂质代谢和与银屑病密切相关的心代谢疾病（CMD）中发挥着不确定的作用。本研究旨在探讨血清肝型脂肪酸结合蛋白（FABP1）水平在银屑病患者中的诊断价值及其与疾病严重程度、炎症或代谢参数的相关性，以及全身治疗的影响。该研究纳入了 33 例活动性斑块型银屑病患者和 11 名健康志愿者。在接受甲氨蝶呤和阿维 A 治疗 12 周前后采集血样。采用酶联免疫吸附试验分析血清 FABP1 浓度。对 FABP1 与人体测量学、代谢或炎症指标及治疗方法的相关性进行了统计学分析。与对照组相比，银屑病患者的血清肝型 FABP 水平显著升高（p<0.001）。未发现 FABP1 与 PASI 之间存在统计学相关性（p=0.25），但重度银屑病患者的 FABP1 水平最高。除治疗后与 BMI 呈正相关（p=0.03）外，与代谢参数无显著相关性。肝型 FABP 与 CRP（p=0.01）和形态学血液成分显著相关。联合全身治疗可显著降低 FABP1（p=0.04），无论药物如何：阿维 A 组 p=0.1，甲氨蝶呤组 p=0.3。肝型 FABP 可能是银屑病的一个新标志物和全身治疗反应的预测因子。FABP1 可能参与 CMDs 风险评估，并将银屑病与血液系统疾病联系起来。
